Gerry Mackay
Tracked across 1 events · 7 articles · First seen Jun 04, 2026 · Last active Jun 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Gerry Mackay, CEO of Refeyn, commented on the significance of the new integrated workflow for characterizing bispecific antibodies, highlighting its ability to address key challenges in the field.
Jun 04, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Gerry Mackay live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard